Dupixent sales reached €4.2 billion in Q3 2025, a 26.2% year-over-year increase
Strong demand across all approved indications drives Dupixent's success
Vaccine sales declined by 7.8% due to lower flu demand
Sanofi maintains its 2025 growth guidance despite vaccine decline